Table 1.
Baseline patient characteristics.
| Characteristics | Number of patients (%) (n = 200) |
|---|---|
| Age (years), median (range) | 55 (28–82) |
| Menopausal status | |
| Premenopausal | 63 (31.5) |
| Postmenopausal | 137 (68.5) |
| Disease-free interval | |
| Primary metastatic | 25 (12.5) |
| ⩽2 years | 30 (15.0) |
| >2 years | 145 (72.5) |
| Metastatic sites | |
| Lung | 73 (36.5) |
| Liver | 118 (59.0) |
| Bone | 143 (71.5) |
| Brain | 11 (5.5) |
| Number of metastatic sites | |
| 1 | 39 (19.5) |
| 2 | 54 (27.0) |
| ⩾3 | 107 (53.5) |
| Visceral metastases | |
| Yes | 164 (82.0) |
| No | 36 (18.0) |
| Lines of advanced systematic therapy of palbociclib | |
| 1 | 35 (17.5) |
| 2 | 54 (27.0) |
| ⩾3 | 111 (55.5) |
| Next-line treatment after progression on palbociclib | |
| Chemotherapy | 147 (73.5) |
| Endocrine therapy | 53 (26.5) |
| Sensitivity to the previous palbociclib | |
| Yes | 96 (48.0) |
| No | 104 (52.0) |